Abstract

The present study aims to collect expert opinions on commonly used angiotensin receptor blockers (ARBs) for reducing blood pressure (BP) and managing associated comorbidities, with a specific emphasis on the use of olmesartan in Indian settings. Methodology: The study used a 22-question questionnaire to gather insights from specialists across different Indian settings regarding their perspectives on ARBs for the management of hypertensive patients with concomitant comorbidities. Results: The present survey study included 986 participants. Olmesartan monotherapy was strongly recommended by 88% of the clinicians for its outstanding BP reduction ability. According to 45% and 48% of the responders, olmesartan monotherapy resulted in a double-digit BP decrease in 25 to 50% and >0% of hypertensive individuals. According to 91% of the respondents, olmesartan offers early BP reduction within two weeks of medication, in terms of additional benefits, 68%, 23%, and 7% of respondents reported that olmesartan can reduce cardiovascular risk, proteinuria, and left ventricular hypertrophy (LVH), respectively. Majority (82% and 80%) of the clinicians recommended olmesartan as the most preferred ARB therapy for hypertensive patients with comorbid diabetes and renal condition. A significant number of respondents (91%) noted that olmesartan treatment confers end-organ protection and a double-digit drop in BP. Conclusion: According to the expert opinion, olmesartan is one of the best ARBs for reducing blood pressure quickly and effectively. The treatment also provides end-organ protection and a decrease in cardiovascular risk and is strongly advised in hypertension patients with concomitant renal and diabetic conditions.

Description